Pancreatic Cancer Treatment Market

Pancreatic Cancer Treatment Market Outlook 2031:

The global pancreatic cancer treatment market size was valued at USD 2.49 Billion in 2022 and is projected to reach USD 9.25 Billion by 2031, expanding at a CAGR of 15.7% during the forecast period 2023 - 2031, attributed to increasing and wide prevalence of consumption of alcohol, obesity, and smoking. Moreover, if an individual in the family history was somehow predisposed to pancreatitis disease, it is likely that children of the individual may develop pancreatic cancer.

When the cells in the pancreas are growing uncontrollably, it leads to pancreatic cancer. The type of cancer is determined by the cells that get affected by cancer and is categorized as endocrine and exocrine. Pancreatic enzymes in the pancreas are created by exocrine and when these cells are affected by cancer, exocrine pancreatic cancer takes place.

Get Free Sample Report

Hormones such as glucagon and insulin are created by endocrine cells, and the presence of cancer cells in these is called endocrine pancreatic cancer. For the diagnosis of this disease, image techniques are used including ultrasound, MRI, and CT scan. The most common therapy provided by oncologists and medical practitioners for treatment is chemotherapy.

At present, the only drugs approved by the U.S Food and Drugs Administration for the treatment of pancreatic cancer treatment are ONIVYDE, ABRAXANE, 5-FU, and Gemzar. Moreover, approval has been granted to a combination of chemotherapies and agents for the treatment of advanced pancreatic cancer and some treatment drugs are under clinical trials.

The COVID-19 pandemic had negative impact on the pancreatic cancer treatment market due to reduced access to hospitals and healthcare services in order to maintain social distancing as per the norms of COVID-19.  Not only the pandemic affected the global economy but also disturbs the normal functioning of hospital care.

The pandemic globally impacted the endoscopy units and several studies showed that a decline in endoscopy was observed during this time. The number of surgeries for pancreatic cancer are also substantially reduced due to the pandemic.

Pancreatic Cancer Treatment Market Trends, Drivers, Restraints, and Opportunities

• Rising incidence and wide prevalence of pancreatic cancer among the geriatric population base is expected to propel the growth of the market in the coming years.
• Advancement in molecular biology, diagnostic technology, and the development of drugs are some of key factors anticipated to fuel the market growth during the forecast period.
• Rising initiatives for research & development, the launch of novel products, and scenarios for favorable reimbursement policies are another factors driving the market growth.
• Diagnostics and treatment of pancreatic cancer are high in cost and regulatory guidelines are strict, which act as major restraining factors. These factors are expected to hamper the market growth during the forecast period.
• In order to improve patient-centered care, a huge amount of funds is continuously invested by the governments in developing countries. This is projected to create lucrative opportunities for the market growth.

Scope of Pancreatic Cancer Treatment Market Report

The report on the global pancreatic cancer treatment market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.

Pancreatic Cancer Treatment Market Segment Insights

Exocrine segment is anticipated to dominate the market

On the basis of affected regions, the global pancreatic cancer treatment market is bifurcated into endocrine and exocrine.

The exocrine segment is expected to dominate the market share in the coming years owing to the increasing reach of novel techniques and rising prevalence.

The endocrine segment, meanwhile, is projected to exhibit a moderate growth rate during the projected period owing to less number of endocrine pancreatic cancer cases as compared to the exocrine segment. However, investments made for research & development are equal in both segments.

Get Free Sample Report

Targeted therapy segment is estimated to account for a key market share

Based on types, the market is categorized as targeted therapy, chemotherapy, and others.

The others segment is further divided into radiation techniques, surgery, and other therapies. The targeted therapy segment is estimated to account for a key market share during the forecast period attributed to the commencement of targeted drugs and novel biologic therapies.

Get Free Sample Report

Asia Pacific is expect to grow at a rapid pace

In terms of regions, the global pancreatic cancer treatment market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa.

North America held a high revenue share of the market in 2019 and is anticipated to register a considerable CAGR during the forecast period. The regional market growth is attributed to the existence of the targeted population, rising adoption of procedures for pancreatic treatment, and increasing improvement of healthcare infrastructure in the region.

However, the market of Asia Pacific is expected to grow at a rapid pace attributed to the high presence of the population suffering from pancreatic cancer, critical care centers, and the presence of hospitals in the region.

Get Free Sample Report

Segments

The global pancreatic cancer treatment market has been segmented on the basis of

Affected Regions

• Endocrine
• Exocrine

Types

• Targeted Therapy
• Chemotherapy
• Others
  • Radiation Techniques
  • Surgery
  • Other Therapies

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Pfizer, Inc.
• Clovis Oncology
• Celgene Corp.
• Amgen, Inc.
• Novartis AG
• PharmaCyte Biotech
• F. Hoffmann-La Roche AG
• IncTeva Pharmaceutical Industries Ltd.
• Merck & Co., Inc.
• Eli Lilly and Co.

Competitive Landscape

Key players competing in the global pancreatic cancer treatment market are Pfizer, Inc.;  Clovis Oncology; Celgene Corp.; Amgen, Inc.; Novartis AG; PharmaCyte Biotech; F. Hoffmann-La Roche AG; IncTeva Pharmaceutical Industries Ltd.; Merck & Co., Inc.; and Eli Lilly and Co.

Many of these players have adopted business strategies such as the launch of new products, advancement of technology, mergers, partnerships, and production capacity expansion to increase their market position and expand their consumer base globally.